Anna Rose Welch articles
-
Aligning With Cancer Centers To Spur Biosimilar Uptake
3/31/2020
During our conversation, Pontchartrain Cancer Center COO Kathy Oubre shared what biosimilar makers can do to balance both sustainability and promote cost savings while also supporting cancer centers and their healthcare professionals.
-
Biosimilars In The Pandemic Age: Current Impact And Market Implications
3/26/2020
This has been a very exciting time for those in drug discovery, while it’s been a bit quieter on the biosimilar front (understandably). That said, I’ve come across a few tidbits of knowledge here and there about the impact this pandemic may or may not yet be having on the biosimilar space.
-
Recent Conference Portrays Progressively Sophisticated Biosimilar Market
3/20/2020
As many of the points shared at the recent World Biosimilar Congress suggest, there have been enough big triumphs in the U.S. and other countries that the discussions surrounding biosimilar education and implementation have and will continue to grow increasingly nuanced.
-
3 Pressing Questions From The FDA/FTC Biologics Competition Workshop
3/13/2020
After taking at least 20 pages of notes from the FDA/FTC biologics competition workshop, I’ve whittled my takeaways down to three overarching questions that provide necessary considerations and industry action steps moving forward.
-
How Biosimilars, Biobetters Fit Into Value-Based Healthcare
3/3/2020
As the buck falls on physicians and healthcare systems to better control the cost of care, I wanted to hear from Dr. Chadi Nabhan about the value-based care models he’s been watching and how biosimilars (and biobetters) could fit into the overarching goals of these arrangements.
-
How Can Hospitals Lead The Biosimilar Charge?
2/25/2020
One oncology expert shares his thoughts on the operational challenges biosimilars may pose hospitals and what biosimilar manufacturers need to consider as they continue to invest in and launch oncology biosimilars.
-
Employers Aim To Transform Biosimilar, Biologics Reimbursement
2/19/2020
Though the IDN is a unique setting of care, there were still several lines of discussion that arose from Kaiser Permanente's best practices that sparked discussion on how other stakeholders, particularly employers, can start to chip away at the systemic issues standing in biosimilars’ way.
-
“What Would Kaiser Do?” Changing The Employer Mindset About Biosimilars
2/12/2020
In this first of a two-part article based on our discussion, a payer and employer coalition director highlight some of the payer and employer-centric discussions that are being had today to both improve biosimilar access and navigate a system that has not been friendly to lower-cost competition thus far.
-
How Kaiser Permanente Built A Biosimilar Empire — The Inside Story
2/7/2020
Kaiser Permanente's Dr. Sameer Awsare and I touched base in recent weeks to talk about the process in place that has encouraged great success for biosimilars within KP. In particular, Dr. Awsare reinforces many of the lessons I’ve heard from other physicians within different healthcare settings in order to encourage greater physician and patient biosimilar buy-in.
-
The Nurse's Perspective On Biosimilars In Oncology Care
1/28/2020
Seeing as Sheldon has been in oncology care for almost 40 years and still works as an oncology nurse practitioner, she was the perfect person to speak to about the trends she’s observing in oncology care, in addition to the current role biosimilars play — and could still play — in oncology.